Furthermore, as a single agent approach, anti-PD1 immunotherapy showed a limited increase in CD8+ cell immune promotion, which could be attributed to lack of CD8+ T cell presence in the tumor microenvironment 26, 41 and potential inability of the antibody to cross the blood brain barrier (BBB). Here, CD8A is linked to neoplasm.